https://orcid.org/0000-0002-9198-9445
References
- Eklund M, Jäderling F, Discacciati A, et al. MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385(10):908–920.
- Nordström T, Discacciati A, Bergman M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22(9):1240–1249.
- Grönberg H, Adolfsson J, Aly M, et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16(16):1667–1676.
- Carlsson S, Assel M, Sjoberg D, et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ.2014;348(mar28 1):g2296–g2296.
- Vertosick EA, Häggström C, Sjoberg DD, et al. Prespecified 4-Kallikrein marker model at age 50 or 60 for early detection of lethal prostate cancer in a large population based cohort of asymptomatic men followed for 20 years. J Urol. 2020;204(2):281–288.
- Boesen L, Norgaard N, Logager V, et al. Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out gleason 7-10 prostate cancer in biopsy-naive men. Eur Urol Oncol. 2019;2(3):311–319.
- Kohestani K, Månsson M, Arnsrud Godtman R, et al. The göteborg prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scand J Urol. 2021;55(2):116–124.
- Auvinen A, Rannikko A, Taari K, et al. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Eur J Epidemiol. 2017;32(6):521–527.
- Bratt O, Öfverholm A. Re: Peter ström, tobiasnordström, henrikgrönberg, martin eklund. The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential. Eur Urol. 2018;74(1):e9.
- Gulati R, Inoue LY, Gore JL, et al. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst. 2014;106(2):djt367.